MAR 19, 2014 12:00 PM PDT

Abeta oligomer receptor antagonists as disease-modifying Alzheimers therapeutics

Presented At Neuroscience
Speakers
  • Founder and Chief Science Officer, Cognition Therapeutics, Inc.
    Biography
      Dr. Susan Catalano received her B.A. from Barnard College and Ph.D. from U.C. Irvine. She completed her postdoctoral training at U.C. Berkeley and Caltech in the field of neurobiology. While a scientist at Roche Palo Alto, she led the Neurophysiology and Neuroimaging groups along with anexploratory program in psychiatric disorders. After Roche, Dr. Catalano joined Rigel Pharmaceuticals, Inc. and led the team that discovered the Aurora kinase inhibitor R763, (licensed to Serono for $135M in 2005.) Dr. Catalano founded a successful consulting practice, Drug Discovery Imaging, and then served as Director of Discovery Biology for Acumen Pharmaceuticals, Inc. Dr. Catalano founded Cognition Therapeutics Inc (www.cogrx.com) in 2007 to discover and develop drugs to treat and prevent Alzheimers disease and currently serves as its Chief Science Officer. The company is currently advancing its candidate drugs towards the clinic. She also volunteers as the Executive Scientific Director of Pittsburgh-based nonprofit the Clear Thoughts Foundation and holds an adjunct appointment at the University of Pittsburgh School of Medicine.

    Abstract:

    Synaptic dysfunction and loss caused by age-dependent accumulation of synaptotoxic Amyloid beta (Abeta)1-42 oligomers is proposed to underlie cognitive decline in Alzheimers disease (AD). Synaptic binding of Abeta oligomers to several putative receptor proteins are reported to inhibit synaptic plasticity mechanisms such as long-term potentiation, affect membrane trafficking and induce reversible spine loss in hippocampal neurons, leading to impaired cognitive performance. We have discovered small molecules with high affinity for Abeta oligomer receptors that displace Abeta oligomer binding in vitro and in human AD patient brain tissue sections in a dose-dependent manner, and both prevent and reverse the effects of Abeta oligomers on membrane trafficking, synapse loss and cognitive deficits in AD mouse models. Our evidence suggests that despite structural heterogeneity, Abeta oligomers bind saturably and reversibly to specific receptors at synapses, and that the Abeta oligomer-induced synaptotoxicity underlying Alzheimers disease has a pharmacological basis that is amenable to treatment with small molecules. The compounds we have discovered therefore represent promising Alzheimers disease-modifying therapeutic drug candidates.


    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    OCT 02, 2019 11:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    OCT 02, 2019 11:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    AUG 13, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 13, 2019 09:00 AM PDT
    DATE: August 13, 2019TIME: 9:00am PT, 12:00pm ET, 5:00pm BST Molecular complexes are major constituents of cells, hence unraveling their mechanisms is key to fuller comprehension of c...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    Loading Comments...
    Show Resources